New Diabetes Drugs in India: SGLT2, GLP-1 & Tirzepatide
A clinical reference on new diabetes drug india options — SGLT2 inhibitors, GLP-1 agonists and tirzepatide — against India's 101-million-patient burden.
This piece covers what these newer drug classes actually do differently, what India-specific outcome data exists for tirzepatide, what RSSDI's own clinical practice recommendations say, and why a hospital pharmacy needs a deliberate stocking strategy for this fast-moving drug category.
What makes SGLT2 inhibitors and GLP-1 agonists different from older diabetes drugs?
SGLT2 inhibitors and GLP-1 receptor agonists both offer cardiometabolic benefits beyond glucose control, including documented cardiovascular and renal protective effects. This distinguishes them from older sulfonylurea and even some earlier insulin-based regimens, whose primary action is glucose-lowering alone. Systematic review evidence supports combining the two classes for additive glycaemic control and cardioprotective effect in appropriately selected patients.
RSSDI's clinical practice recommendations for type 2 diabetes management in India, evaluated as a high-quality guideline in a published systematic review of Indian diabetes guidance, incorporate this newer evidence base directly rather than treating these drug classes as a later-line option only.
What is tirzepatide, and is there Indian-specific data on it?
Tirzepatide is a once-weekly dual GIP and GLP-1 receptor agonist, a newer mechanism distinct from single-target GLP-1 agonists, first approved for type 2 diabetes management based on trial data showing superior glycaemic efficacy compared to existing agents. A published real-world study in Indian adults with type 2 diabetes found significant early glycaemic and cardiometabolic improvement with tirzepatide use, one of the first India-specific outcome datasets for this drug class.
This India-specific real-world evidence matters because trial populations and real-world Indian patients often differ in body composition, diet and comorbidity pattern, and a hospital adopting a new diabetes drug India-wide clinical trials haven't tested locally benefits from exactly this kind of local outcome data before setting institutional prescribing policy.
How large is India's diabetes burden, and why does it matter for drug stocking?
The ICMR-INDIAB national cross-sectional study, covering more than 113,000 participants across every Indian state and union territory, found an overall weighted diabetes prevalence of 11.4%, translating to an estimated 101 million people living with diabetes nationally, alongside 136 million with prediabetes. The same study found diabetes prevalence higher in urban areas than rural ones, a pattern relevant to how a hospital forecasts demand by catchment population.
A national diabetes population this large means the newer drug classes described here are not a niche prescribing choice; they represent a growing share of a very large existing patient base, and pharmacy stocking plans built around older sulfonylurea-dominant assumptions understate real demand.
What does India's government guidance say about diabetes treatment updates?
Government communication on diabetes treatment in India has specifically acknowledged the shifting therapeutic landscape as newer drug classes enter clinical use, alongside the country's National Programme for Prevention and Control of Non-Communicable Diseases framework for diabetes screening and management at the primary-care level. This national programme infrastructure is where most of India's diabetes population is actually screened and managed, not tertiary-care endocrinology alone.
A hospital pharmacy's stocking decisions for these newer drug classes should account for this dual reality. A small number of patients need complex, high-cost newer therapy. A much larger population is managed through simpler primary-care-level protocols that still need reliable metformin and sulfonylurea stock as the actual first-line backbone.
What precautions matter with these newer diabetes drug classes?
SGLT2 inhibitors carry a documented risk of genital mycotic infection and, less commonly, diabetic ketoacidosis even at near-normal glucose levels, a distinct pattern requiring specific patient counselling different from older oral agents. GLP-1 and dual-agonist therapies carry gastrointestinal side effects, most commonly nausea, that are usually dose-related and managed through gradual titration under the treating physician's supervision.
None of this substitutes for an individual prescribing decision; it is the class-level caution profile relevant to a hospital pharmacist counselling a patient starting one of these newer therapies for the first time.
Why does reliable in-house stocking of newer diabetes drugs matter for continuity of care?
A patient started on an SGLT2 inhibitor, GLP-1 agonist or tirzepatide during a hospital consultation needs that exact drug and dose available at every subsequent refill, given how central consistent dosing is to these agents' cardiometabolic benefit. When a hospital's own pharmacy can't reliably stock a newer, sometimes higher-cost diabetes drug, that prescription, and the revenue and continuity that come with it, moves to an outside chemist.
Our prescription leakage guide covers what this walk-out costs a hospital across what is typically a lifelong diabetes-care relationship, and our managed hospital pharmacy services piece covers how reliable in-house stocking of both newer, higher-value diabetes drugs and the older first-line backbone keeps a diabetes patient's full treatment inside one pharmacy system.
Sources
- 1Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17) — The Lancet Diabetes & Endocrinology
- 2Update on treatment of Diabetes — Press Information Bureau, Government of India
- 3RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017 — National Institutes of Health, National Library of Medicine
- 4Real-World Evidence of Tirzepatide in Indian Adults With Type 2 Diabetes — National Institutes of Health, National Library of Medicine
- 5National List of Essential Medicines 2022 — Central Drugs Standard Control Organisation
This article is for informational purposes and is not a substitute for professional medical advice. Drug choice for diabetes management is a clinical decision for the treating doctor based on the individual patient's full risk profile. Consult a qualified physician before starting or changing any treatment.
FAQ
Frequently asked questions
SGLT2 inhibitors, GLP-1 receptor agonists, and the dual GIP/GLP-1 agonist tirzepatide represent the newest widely used diabetes drug classes in Indian practice, each offering cardiometabolic benefits documented beyond glucose control alone.
Yes, a published real-world study in Indian adults with type 2 diabetes found significant early glycaemic and cardiometabolic improvement with tirzepatide, one of the first locally generated outcome datasets for this drug class.
The ICMR-INDIAB national study estimates around 101 million people in India live with diabetes, with a further 136 million living with prediabetes, based on a cross-sectional survey of more than 113,000 participants across every state and union territory.
SGLT2 inhibitors carry a documented risk of genital mycotic infection and, less commonly, diabetic ketoacidosis even at near-normal glucose levels, so patient selection and counselling are a clinical decision for the treating physician rather than a universal default choice.
No. Metformin and, where appropriate, sulfonylureas remain the primary-care-level first-line backbone for most of India's diabetes population under national screening and management programmes, with newer classes typically added or substituted based on individual cardiometabolic risk and response.
Dr. Ananya DeshpandeMBBS, DM (Endocrinology)
Consultant Endocrinologist
Dr. Ananya Deshpande is a consultant endocrinologist writing on diabetes and insulin therapy, thyroid disorders, GLP-1 agonists, and metabolic conditions.